ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A consortium of investors have revived Icelandic biotech firm deCode Genetics as a private company with fresh financing after its parent company declared bankruptcy in November 2009. Saga Investments, which includes Polaris Ventures and Arch Venture Partners, bought the firm from its publicly held parent company, which has changed its name to DGI Resolution while it liquidates remaining assets. With Earl M. Collier Jr., former executive vice president at Genzyme, at the helm and deCode’s former CEO Kári Stefánsson as president of research, the new deCode will continue to sell diagnostic tests, offer personal genome scans, and provide a range of contract services. deCode was started in 1996 to tap into the homogeneity of the Icelandic population in order to determine the genetic underpinnings of disease. Although the company found endless “links” to diseases, it failed to translate those data into products.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X